Payment overview · 2025
General Payments
$1,132.54
44 reported records · 14 companies
Healthcare provider profile · identity verified
Gustavo Serrano, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · TAMPA, FL · NPI 1396732442
Verified facts
What the public records show
CMS Open Payments records show Gustavo Serrano, MD received $1,132.54 in general payments during 2025 across 44 reported records.
AstraZeneca Pharmaceuticals LP accounted for 22.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 212 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $253.97 | 22.4% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $197.47 | 17.4% | 7 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $159.40 | 14.1% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $142.55 | 12.6% | 9 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $70.21 | 6.2% | 3 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $57.17 | 5.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $50.00 | 4.4% | 3 | 2025 |
| INOGEN, INC. | Unresolved — no canonical attribution shown | $48.85 | 4.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $45.16 | 4.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $29.48 | 2.6% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.76 | 2.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.27 | 2.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.68 | 1.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.57 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,113.69 | 43 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $256.98 | 11 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $164.86 | 2 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $159.40 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $89.11 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $83.04 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $70.21 | 3 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $57.17 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $50.00 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $50.00 | 3 | 2025 |
Source payment records
|
|||||
| INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH Normalized: inogen one g5 oxygen concentrator bluetooth |
Device | INOGEN, INC. | $48.85 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $47.80 | 1 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $45.16 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $38.52 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $29.48 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $29.48 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $29.48 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $22.76 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $22.27 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $18.68 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 212 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 67 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 32 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 92 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
32 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
212 | 51 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
47 | 17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
92 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
150 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 695 | 185 |
| Amlodipine Besylate | Amlodipine Besylate | 352 | 113 |
| Metformin Hcl | Metformin Hcl | 323 | 83 |
| Alendronate Sodium | Alendronate Sodium | 270 | 75 |
| Diclofenac Sodium | Diclofenac Sodium | 262 | 71 |
| Gabapentin | Gabapentin | 259 | 76 |
| Levothyroxine Sodium | Levothyroxine Sodium | 249 | 55 |
| Losartan Potassium | Losartan Potassium | 247 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 247 | 78 |
| Allopurinol | Allopurinol | 237 | 73 |
| Carvedilol | Carvedilol | 212 | 68 |
| Farxiga | Dapagliflozin Propanediol | 212 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 201 | 55 |
| Meloxicam | Meloxicam | 199 | 51 |
| Omeprazole | Omeprazole | 194 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 183 | 62 |
| Famotidine | Famotidine | 183 | 54 |
| Trazodone Hcl | Trazodone Hcl | 183 | 48 |
| Furosemide | Furosemide | 175 | 53 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 168 | 39 |
| Glipizide | Glipizide | 159 | 51 |
| Montelukast Sodium | Montelukast Sodium | 156 | 38 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 153 | 51 |
| Eliquis | Apixaban | 150 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 144 | 42 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 143 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 142 | 41 |
| Lisinopril | Lisinopril | 142 | 47 |
| Lorazepam | Lorazepam | 133 | 30 |
| Azithromycin | Azithromycin | 129 | 91 |
| Pravastatin Sodium | Pravastatin Sodium | 127 | 37 |
| Clonidine Hcl | Clonidine Hcl | 122 | 36 |
| Potassium Chloride | Potassium Chloride | 115 | 37 |
| Simvastatin | Simvastatin | 115 | 34 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 113 | 38 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 110 | 31 |
| Ibuprofen | Ibuprofen | 105 | 31 |
| Sertraline Hcl | Sertraline Hcl | 105 | 28 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 103 | 70 |
| Ozempic | Semaglutide | 102 | 17 |
| Tramadol Hcl | Tramadol Hcl | 95 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 94 | 27 |
| Mounjaro | Tirzepatide | 92 | 15 |
| Prednisone | Prednisone | 89 | 58 |
| Fluticasone Propionate | Fluticasone Propionate | 86 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 85 | 26 |
| Temazepam | Temazepam | 85 | 17 |
| Spironolactone | Spironolactone | 84 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 78 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 75 | 22 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 72 | 26 |
| Cephalexin | Cephalexin | 71 | 58 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 70 | 21 |
| Humalog Kwikpen U-100 | Insulin Lispro | 68 | 18 |
| Jardiance | Empagliflozin | 67 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 66 | 23 |
| Naproxen | Naproxen | 66 | 25 |
| Baclofen | Baclofen | 65 | 29 |
| Megestrol Acetate | Megestrol Acetate | 62 | 19 |
| Nifedipine Er | Nifedipine | 62 | 18 |
| Alcohol Pads | Alcohol Antiseptic Pads | 60 | 16 |
| Clonazepam | Clonazepam | 58 | suppressed |
| Januvia | Sitagliptin Phosphate | 58 | 17 |
| Sucralfate | Sucralfate | 57 | 14 |
| Meclizine Hcl | Meclizine Hcl | 56 | 17 |
| Nitroglycerin | Nitroglycerin | 56 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 55 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 55 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 54 | 14 |
| Buspirone Hcl | Buspirone Hcl | 51 | 14 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 50 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 49 | 15 |
| Hydrocortisone | Hydrocortisone | 49 | suppressed |
| Calcitriol | Calcitriol | 48 | 17 |
| Symbicort | Budesonide/Formoterol Fumarate | 47 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 45 | 18 |
| Ketoconazole | Ketoconazole | 45 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 44 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | suppressed |
| Valsartan | Valsartan | 44 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | 17 |
| Lidocaine | Lidocaine | 43 | 12 |
| Memantine Hcl | Memantine Hcl | 42 | 11 |
| Novolog Flexpen | Insulin Aspart | 42 | 13 |
| Prosol | Parenteral Amino Acid 20% No.1 | 42 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 30 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 40 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 39 | 12 |
| Atenolol | Atenolol | 38 | 13 |
| Dutasteride | Dutasteride | 38 | 12 |
| Glimepiride | Glimepiride | 38 | 12 |
| Methotrexate | Methotrexate Sodium | 37 | suppressed |
| Telmisartan | Telmisartan | 35 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 35 | 27 |
| Bumetanide | Bumetanide | 34 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 33 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 33 | suppressed |
| Glipizide Er | Glipizide | 33 | suppressed |
| Methocarbamol | Methocarbamol | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Linzess | Linaclotide | 32 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 28 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | 11 |
| Calcium Acetate | Calcium Acetate | 29 | 13 |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 29 | suppressed |
| Pregabalin | Pregabalin | 29 | suppressed |
| Ciclopirox | Ciclopirox | 28 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | 12 |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Lactulose | Lactulose | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 24 |
| Cefdinir | Cefdinir | 26 | 22 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 23 | suppressed |
| Levemir Flexpen | Insulin Detemir | 22 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Clonidine | Clonidine | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 19 |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Minoxidil | Minoxidil | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 12 |
| Ibandronate Sodium | Ibandronate Sodium | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Alprazolam | Alprazolam | 15 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Levemir | Insulin Detemir | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Ssd | Silver Sulfadiazine | 15 | suppressed |
| Cordran | Flurandrenolide | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 11 |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Velphoro | Sucroferric Oxyhydroxide | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Efavirenz-Emtric-Tenofov Disop | Efavirenz/Emtricit/Tenofovr Df | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Veo Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,132.54 · 44 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, ACCRUFER, AIRSUPRA, BREZTRI, COMIRNATY, FARXIGA, GVOKE HYPOPEN, INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH, JARDIANCE, JYNARQUE, Kerendia, LINZESS, MOUNJARO, OTEZLA, PREVNAR 20, REPATHA, TARPEYO, TRELEGY ELLIPTA, XIFAXAN, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error